Skip to main content
Livermore
Livermore
ZHEN

ESSA Pharma Inc.

EPIXDelisted Oct 9, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001633932

ESSA Pharma Inc. was delisted on Oct 9, 2025; its insiders filed their last Form 4 on Oct 15, 2025; 32 institutions reported holding it in 13F filings for Q3 2025, worth $4.30M in total; no superinvestor held it.

Holders of 5% or more of EPIX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of ESSA Pharma Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of EPIX
HolderLatest formStakeChangeFirst filedLatest filingFiling
Soleus Capital Master Fund, L.P.13D/A9.80%4.36M shares+4.70 ppfrom 5.10%Apr 15, 20253 filingsJul 21, 2025SEC
BML Investment Partners, L.P.13D9.50%4.22M shares0.00 ppfrom 9.50%Feb 14, 20253 filingsApr 24, 2025SEC
Soleus Capital, LLC13G/A5.10%2.26M shares–Feb 12, 20215 filingsFeb 11, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

51 Schedule 13D and 13G filings on ESSA Pharma Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on EPIX
Filed (ET)FilerFormStakeChangeEvent dateFiling
Feb 16, 2021Driehaus Capital Management LLC13GOld format–New–SEC
Feb 12, 2021Eventide Asset Management, LLC13G/AOld format–––SEC
Feb 12, 2021Vivo Capital IX, LLC13G/AOld format–––SEC
Feb 12, 2021Omega Fund IV, L.P.13G/AOld format–––SEC
Feb 12, 2021Soleus Capital, LLC13G/AOld format–––SEC
Feb 11, 2021Biotechnology Value Fund L P13G/AOld format–––SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell ESSA Pharma Inc. shares.

No Form 144 notices for ESSA Pharma Inc. are on file.